🟢 United Therapeutics is trading 4.59% up today after FDA clearance for Phase 2 SUMMIT trial

United Therapeutics is trading at $557.62, up 4.59%, after FDA clearance to start its Phase 2 SUMMIT trial.

• On October 19, the FDA cleared the company to start its trial of treprostinil SMI in patients with pulmonary hypertension associated with COPD.
• The 16-week study will assess safety and tolerability in approximately 40 patients.
• Biotech shares rose 2.09% during the regular session, a supportive backdrop that may have contributed to the gain; the prior close was $533.12.